Table 2.
Univariable |
Multivariable |
||||
---|---|---|---|---|---|
St. Beta | P-value | St. Beta | P-value | Part correlation | |
Demographics | |||||
Age, years | −0.176 | <0.001 | −0.190 | <0.001 | −0.148 |
Diabetes duration, years | 0.012 | 0.355 | 0.115 | 0.006 | 0.098 |
Male gender (male = 1) | −0.162 | <0.001 | 0.219 | <0.001 | 0.138 |
Current smoker | −0.012 | 0.363 | −0.060 | 0.119 | −0.056 |
BMI, kg/m2 | −0.171 | <0.001 | −0.164 | <0.001 | −0.149 |
Systolic blood pressure, mm Hg | −0.051 | <0.001 | 0.016 | 0.714 | 0.013 |
Diastolic blood pressure, mm Hg | −0.054 | <0.001 | −0.093 | 0.033 | −0.076 |
Complications | |||||
Microvascular complications | −0.070 | <0.001 | −0.088 | 0.282 | −0.039 |
Micro-albuminuria | 0.000 | 0.986 | 0.046 | 0.499 | 0.024 |
Macro-albuminuria | −0.064 | <0.001 | 0.080 | 0.298 | 0.037 |
Retinopathy | −0.091 | <0.001 | −0.035 | 0.490 | −0.027 |
Neuropathy | −0.065 | <0.001 | −0.024 | 0.685 | −0.015 |
Macrovascular complications | −0.054 | <0.001 | −0.127 | 0.024 | −0.081 |
Angina pectoris | 0.001 | 0.935 | 0.068 | 0.089 | 0.061 |
Myocardial infarction | −0.057 | <0.001 | −0.013 | 0.791 | 0.009 |
PTCA | −0.026 | 0.049 | 0.000 | 0.994 | 0.000 |
CABG | −0.056 | <0.001 | −0.036 | 0.368 | −0.032 |
TIA | 0.055 | <0.001 | 0.068 | 0.086 | 0.062 |
CVA | 0.048 | <0.001 | 0.036 | 0.336 | 0.034 |
Heart failure | −0.074 | <0.001 | −0.065 | 0.087 | −0.061 |
Laboratory Measurements | |||||
HbA1c, mmol/mol | −0.135 | <0.001 | −0.204 | <0.001 | −0.182 |
Creatinine , µmol/L | −0.123 | <0.001 | −0.123 | 0.110 | −0.057 |
eGFR (MDRD), ml/min/1.73 m2 | 0.036 | 0.007 | 0.097 | 0.167 | 0.050 |
Total cholesterol, mmol/L | −0.030 | 0.025 | 0.226 | 0.279 | 0.039 |
Total cholesterol:HDL ratio | −0.060 | <0.001 | −0.193 | 0.129 | −0.054 |
HDL cholesterol, mmol/L | 0.022 | 0.102 | −0.169 | 0.205 | −0.045 |
LDL cholesterol, mmol/L | −0.034 | 0.011 | −0.073 | 0.584 | −0.016 |
Triglycerides, mmol/L | −0.055 | <0.001 | −0.018 | 0.810 | −0.009 |
Albumin:creatinine ratio, mg/mmol | −0.089 | <0.001 | −0.059 | 0.477 | −0.025 |
Medication | |||||
Dietary measures only | −0.064 | <0.001 | 0.121 | 0.229 | 0.041 |
Oral blood glucose lowering drugs | 0.087 | <0.001 | 0.025 | 0.849 | 0.007 |
Metformin | 0.104 | <0.001 | 0.125 | 0.155 | 0.049 |
Sulfonylurea derivatives | 0.026 | 0.053 | 0.019 | 0.632 | 0.017 |
Thiazolinediones | −0.046 | 0.001 | −0.044 | 0.230 | −0.041 |
DDP4 inhibitors | −0.002 | 0.872 | −0.027 | 0.447 | −0.026 |
Insulin | −0.015 | 0.254 | 0.066 | 0.123 | 0.053 |
Antihypertensive drugs | −0.075 | <0.001 | −0.051 | 0.232 | −0.041 |
Diuretics | −0.050 | <0.001 | −0.031 | 0.426 | −0.027 |
Beta blockers | −0.005 | 0.723 | 0.044 | 0.270 | 0.038 |
Calcium antagonists | −0.035 | 0.011 | −0.031 | 0.399 | −0.029 |
RAAS blockers | −0.012 | 0.367 | 0.043 | 0.295 | 0.036 |
Cholesterol lowering drugs | 0.013 | 0.343 | −0.018 | 0.619 | −0.017 |
Thrombocyte aggregation inhibitor | 0.044 | 0.001 | 0.137 | 0.001 | 0.116 |
Significant (p < 0.05) values are emphasized in bold. Abbreviations: BMI, body mass index; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; TIA, transient ischemic attack; CVA, cerebral vascular event; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, high-density lipoprotein; DDP4, dipeptidyl peptidase 4; RAAS, renin-angiotensin-aldosterone system; R-SH, total free thiol groups.